Your browser doesn't support javascript.
Blood Hemoglobin Substantially Modulates the Impact of Gender, Morbid Obesity, and Hyperglycemia on COVID-19 Death Risk: A Multicenter Study in Italy and Spain.
Mayneris-Perxachs, Jordi; Russo, Maria Francesca; Ramos, Rafel; de Hollanda, Ana; Arxé, Arola Armengou; Rottoli, Matteo; Arnoriaga-Rodríguez, María; Comas-Cufí, Marc; Bartoletti, Michele; Verrastro, Ornella; Gudiol, Carlota; Fages, Ester; Giménez, Marga; Gil, Ariadna de Genover; Bernante, Paolo; Tinahones, Francisco; Carratalà, Jordi; Pagotto, Uberto; Hernández-Aguado, Ildefonso; Fernández-Aranda, Fernando; Meira, Fernanda; Castro Guardiola, Antoni; Mingrone, Geltrude; Fernández-Real, José Manuel.
  • Mayneris-Perxachs J; Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, Girona, Spain.
  • Russo MF; Nutrition, Eumetabolism and Health Group, Girona Biomedical Research Institute (IdibGi), Girona, Spain.
  • Ramos R; Department of Endocrinology and Nutrition, Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain.
  • de Hollanda A; Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Università Cattolica del Sacro Cuore Rome, Rome, Italy.
  • Arxé AA; Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain.
  • Rottoli M; Vascular Health Research Group of Girona (ISV-Girona). Jordi Gol Institute for Primary Care Research (Institut Universitari per a la Recerca en AtencióPrimària Jordi Gol I Gurina -IDIAPJGol), Girona Biomedical Research Institute (IDIBGI), Dr. Josep Trueta University Hospital, Catalonia, Spain.
  • Arnoriaga-Rodríguez M; Girona Biomedical Research Institute (IDIBGI), Dr. Josep Trueta University Hospital, Catalonia, Spain.
  • Comas-Cufí M; Department of Endocrinology & Nutrition, Hospital Clínic Barcelona, Diabetes Unit, Barcelona, Spain.
  • Bartoletti M; Department of Endocrinology and Nutrition, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Verrastro O; Department of Internal Medicine, Service of Internal Medicine Dr. Josep Trueta University Hospital, Catalonia, Spain.
  • Gudiol C; Department of Surgery, Diabetology and Otolaryngology, Surgery of the Alimentary Tract and Centre for the Study and Research of Treatment for Morbid Obesity, Bologna, Italy.
  • Fages E; Infectious Diseases Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Sant'Orsola Policlinic, Bologna, Italy.
  • Giménez M; Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, Girona, Spain.
  • Gil AG; Nutrition, Eumetabolism and Health Group, Girona Biomedical Research Institute (IdibGi), Girona, Spain.
  • Bernante P; Department of Endocrinology and Nutrition, Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain.
  • Tinahones F; Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain.
  • Carratalà J; Vascular Health Research Group of Girona (ISV-Girona). Jordi Gol Institute for Primary Care Research (Institut Universitari per a la Recerca en AtencióPrimària Jordi Gol I Gurina -IDIAPJGol), Girona Biomedical Research Institute (IDIBGI), Dr. Josep Trueta University Hospital, Catalonia, Spain.
  • Pagotto U; Infectious Diseases Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Sant'Orsola Policlinic, Bologna, Italy.
  • Hernández-Aguado I; Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Università Cattolica del Sacro Cuore Rome, Rome, Italy.
  • Fernández-Aranda F; Department of Infectious Diseases, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
  • Meira F; Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
  • Castro Guardiola A; Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain.
  • Mingrone G; Department of Clinical Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • Fernández-Real JM; Department of Oncology, Institut Català d'Oncologia (ICO) Hospitalet de Llobregat, Barcelona, Spain.
Front Endocrinol (Lausanne) ; 12: 741248, 2021.
Article in English | MEDLINE | ID: covidwho-1526766
ABSTRACT

Background:

Hyperglycemia and obesity are associated with a worse prognosis in subjects with COVID-19 independently. Their interaction as well as the potential modulating effects of additional confounding factors is poorly known. Therefore, we aimed to identify and evaluate confounding factors affecting the prognostic value of obesity and hyperglycemia in relation to mortality and admission to the intensive care unit (ICU) due to COVID-19.

Methods:

Consecutive patients admitted in two Hospitals from Italy (Bologna and Rome) and three from Spain (Barcelona and Girona) as well as subjects from Primary Health Care centers. Mortality from COVID-19 and risk for ICU admission were evaluated using logistic regression analyses and machine learning (ML) algorithms.

Results:

As expected, among 3,065 consecutive patients, both obesity and hyperglycemia were independent predictors of ICU admission. A ML variable selection strategy confirmed these results and identified hyperglycemia, blood hemoglobin and serum bilirubin associated with increased mortality risk. In subjects with blood hemoglobin levels above the median, hyperglycemic and morbidly obese subjects had increased mortality risk than normoglycemic individuals or non-obese subjects. However, no differences were observed among individuals with hemoglobin levels below the median. This was particularly evident in men those with severe hyperglycemia and hemoglobin concentrations above the median had 30 times increased mortality risk compared with men without hyperglycemia. Importantly, the protective effect of female sex was lost in subjects with increased hemoglobin levels.

Conclusions:

Blood hemoglobin substantially modulates the influence of hyperglycemia on increased mortality risk in patients with COVID-19. Monitoring hemoglobin concentrations seem of utmost importance in the clinical settings to help clinicians in the identification of patients at increased death risk.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Obesity, Morbid / Glycated Hemoglobin / COVID-19 / Hyperglycemia Type of study: Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Front Endocrinol (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fendo.2021.741248

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Obesity, Morbid / Glycated Hemoglobin / COVID-19 / Hyperglycemia Type of study: Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Front Endocrinol (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fendo.2021.741248